S. Rossi

NEMESI: A retrospective observational longitudinal study to investigate italian early breast cancer (EBC) patient characteristics and treatment.

V. Adamo, F. Cognetti, A. Gardini, 2010 .

Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies

G. Ceresoli, V. Vavassori, E. D'Argento, 2021, ESMO open.

CMF + radiotherapy in the primary treatment of operable breast cancer: Preliminary results of a phase II pilot study

C. Lombardi, M. Raffaelli, R. Bellantone, 1998, Journal of surgical oncology.

Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment.

P. Foggi, P. Vici, D. Sergi, 2008, Clinica Terapeutica.

Association of non-Hodgkin's lymphoma and hepatocellular carcinoma.

L. Cavanna, M. Di Stasi, L. Buscarini, 1990, Oncology.

1105PVEMURAFENIB FOR BRAF V600 MUTATED ADVANCED MELANOMA: RESULTS OF TREATMENT BEYOND PROGRESSION.

Y. S. Kim, Su Jin Lee, J. Utikal, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway

R. Bristow, G. Calin, S. Rossi, 2016, Oncogene.

Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.

M. Mottolese, P. Foggi, P. Perri, 2008, La Clinica terapeutica.